AbCellera Biologics shares jump 10.40% intraday after initiating Phase 2 trial for ABCL635 in menopausal symptoms.

AbCellera Biologics surged 10.40% intraday after announcing the initiation of the Phase 2 portion of its Phase 1/2 trial for ABCL635, a first-in-class non-hormonal treatment for menopausal vasomotor symptoms. The clinical milestone, highlighted in a Simply Wall St analysis, underscores the company’s progress in advancing its internal pipeline, which had already driven a 15.05% 30-day return and 24.78% year-to-date gain. While the stock trades at a 36.3x price-to-sales ratio—well above industry peers—the article noted a discounted cash flow model suggested shares were 74.9% undervalued at $4.28, reinforcing optimism about future cash flow potential. The news aligns with the intraday rally, as investors appear to price in improved sentiment following recent clinical advancements and a potential reset in valuation expectations.